Pharmaceuticals · GLAND
Pharma - API & CRAMS
from 2,667 today
Gland Pharma delivered a better-than-expected financial performance in 1QFY27, driven by robust growth in the US and EU markets. We value GLAND at 30x 12-month forward earnings to arrive at a TP of INR3,080 and reiterate BUY.
Gland Pharma reported a strong Q1FY27 with 19.6% YoY consolidated revenue growth to Rs 1,800 Cr, driven by broad-based growth across its base business and continued acceleration in the CDMO segment. Management reiterated guidance for 15% constant currency revenue growth in FY27, supported by new launches, volume expansion, operational progress in Cenexi, and major strategic CDMO contract wins.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
